Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2004

View Archived Issues

Artekin may contribute to control of multidrug-resistant malaria

Enrollment complete in phase IV Visicol constipation study

Preclinical evidence for the antiviral efficacy of interferon alpha in SARS

Duloxetine improves voiding and quality of life of women with stress urinary incontinence

Clinical development of CAB-175 discontinued

Genzyme to acquire Ilex Oncology

Reorganization of indiplon agreements

Active Biotech discontinues discovery projects, focuses on development

Biovail acquires rights to novel formulations of eprosartan and carvedilol

Reolysin program update

Integrin alphavbeta3 antagonist and bone resorption inhibitor characterized for further development

Randomization completed in candesartan diabetic retinopathy program

Pharmacological characterization of novel DPP IV inhibitor K-579

Successful completion of first phase I trial for nebulized rAAT

Identification of neural stem cells in adult human brain

Improved response found in vitiligo patches with tacrolimus and excimer laser

Four related series of LDL receptor upregulators presented by GSK

New antibacterial oxazolidinones presented by Orchid researchers

Novel HDAC inhibitors prepared and tested by 4SC and G2M scientists

New glucosylceramide synthase inhibitors identified at Oxford Glycosciences

Aventis claims the preparation and use of novel cysteine protease inhibitors

New xanthine oxidase inhibitors for inflammation, reperfusion disorders and gout

Uriach presents immunomodulators and proapoptotic agents in a recent patent

Two novel series of glycogenphosphorylase a inhibitors under study at Aventis

Sinus and Allergy Health Partnership guidelines recommend Omnicef

Kirin announces phase I clinical trial of KRN-125 and other recent developments

Preclinical data supports use of INGN-241 regimens for lung, breast cancer

Satraplatin shows in vitro efficacy in tumor cells resistant to Taxotere and Taxol

Advanced Viral Research reports in vitro biologic effects of AVR-118

Approvable letter for Estorra

Zadaxin shows efficacy in preclinical invasive aspergillosis study

Investigation of Viagra for FSAD to close

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...